Hair Loss Causes: The Complete Cause-to-Treatment Map for 2026

Introduction: The Question Behind “Why Am I Losing Hair?”

It often starts with a small observation: more strands in the shower drain, a hairline that looks slightly higher in photos, or a part that seems wider than it used to be. For most people, that moment brings anxiety and a pressing question before any decision about treatment: why is this happening?

Most online resources separate “causes” from “treatment,” or list statistics without explaining how hair loss actually works. Readers come away with more information but no closer to knowing what to do.

This guide takes a different approach. It organizes hair loss into six clinically recognized categories:

  1. Androgenetic alopecia
  2. Telogen effluvium
  3. Anagen effluvium
  4. Alopecia areata
  5. Traction alopecia and trichotillomania
  6. Scarring (cicatricial) alopecia

By the end, readers should understand which category they most likely fall into, whether that cause is reversible or progressive, and what a specialist would typically recommend next.

The stakes go beyond appearance. Nearly half of people with hair loss meet criteria for a clinical anxiety disorder, with a 39% lifetime prevalence of depression among those affected. For that reason, Hair Transplant Specialists approaches this topic as a clinical guide first. Understanding the cause comes before any conversation about solutions.

Why Category Matters More Than Symptoms Alone

Surface symptoms often look alike. Diffuse thinning can come from a hormonal pattern, a nutritional deficiency, or a recent illness. Patches can be autoimmune, fungal, or the result of hair pulling. This is why judging by appearance alone is unreliable.

The most important clinical distinction is reversible versus permanent or progressive hair loss. Some causes resolve once a trigger is removed. Others continue to advance without treatment.

Nonscarring alopecia, which includes androgenetic alopecia, accounts for approximately 95% of all hair loss cases. Scarring alopecia is rarer, but it is the category where early detection matters most.

According to the American Academy of Dermatology, effective treatment for hair loss begins with finding the cause. That clinical logic shapes every section below, where each category is explained by mechanism, common triggers, reversibility, and the appropriate clinical response.

The Six Clinical Categories of Hair Loss at a Glance

  • Androgenetic alopecia

    • Pattern: Receding hairline or crown thinning (men); diffuse thinning at the crown (women)
    • Cause: Genetics and DHT sensitivity
    • Reversibility: Progressive and permanent without treatment
    • Direction: Medical therapy, then possible surgical restoration
  • Telogen effluvium

    • Pattern: Sudden, diffuse shedding
    • Cause: Physical or emotional shock, thyroid imbalance, nutritional deficiency
    • Reversibility: Typically reversible
    • Direction: Identify and correct the trigger
  • Anagen effluvium

    • Pattern: Rapid, severe loss within days to weeks
    • Cause: Chemotherapy, radiation, toxic exposure
    • Reversibility: Usually reversible after exposure ends
    • Direction: Supportive care and medical coordination
  • Alopecia areata

    • Pattern: Round or oval bald patches
    • Cause: Autoimmune attack on follicles
    • Reversibility: Unpredictable
    • Direction: Dermatological and immunological treatment
  • Traction alopecia and trichotillomania

    • Pattern: Loss at tension points or pulling sites
    • Cause: Tight hairstyles or compulsive pulling
    • Reversibility: Reversible early; can become permanent
    • Direction: Behavioral change, then possible restoration
  • Scarring alopecia

    • Pattern: Smooth, shiny patches, sometimes with inflammation
    • Cause: Inflammation that destroys follicles
    • Reversibility: Permanent
    • Direction: Stop inflammation urgently, then consider restoration

Androgenetic alopecia affects roughly 80 million men and women in the United States, which makes it the most common starting hypothesis. It is not the only possibility, however, and categories frequently overlap.

Category 1: Androgenetic Alopecia (Pattern Hair Loss)

Androgenetic alopecia is the most common cause of hair loss worldwide, and the same medical term applies whether it develops in a man or a woman.

The mechanism centers on elevated levels of 5-alpha-reductase, an enzyme that converts testosterone to dihydrotestosterone (DHT). In genetically susceptible follicles, DHT drives progressive miniaturization: hairs grow thinner, shorter, and weaker until the follicle stops producing visible hair. The genetics are complex; researchers have identified more than 380 genetic loci associated with the condition.

Prevalence is striking. By age 35, approximately 40% of men experience significant hair loss, a figure that can rise to 80% by age 70. By age 65, an estimated 53% of men and 37% of women will experience baldness.

The key fact to understand: without medication or treatment, hair loss from androgenetic alopecia is permanent and progressive.

Recognizing the Pattern

In men, it typically appears as a receding hairline at the temples and thinning at the vertex, classified on the Norwood scale. In women, it usually presents as diffuse thinning across the crown with the frontal hairline preserved, classified on the Ludwig scale. Onset is gradual and progressive rather than sudden.

The Clinical Response: What a Specialist Recommends

  • First-line medical therapy: Finasteride reduces DHT levels, and minoxidil stimulates follicles to support regrowth. Both are primarily aimed at slowing progression and preserving existing hair.
  • An evolving field: Clascoterone 5% topical solution showed strong Phase 3 results in December 2025, with up to 539% relative improvement in hair count versus placebo. It could become the first new FDA-approved mechanism for androgenetic alopecia in three decades.
  • Surgical restoration: For stabilized or advanced pattern loss, FUE (Follicular Unit Extraction) and FUT (Follicular Unit Transplantation) relocate DHT-resistant follicles to thinning areas as a permanent restorative solution, ideally once medical therapy has been optimized.

Because this cause is progressive, early intervention preserves more options. The more native hair a patient keeps, the more flexibility exists for both medical and surgical approaches later.

Category 2: Telogen Effluvium (Stress-Triggered Shedding)

Telogen effluvium is diffuse shedding caused by a shock to the system that pushes large numbers of follicles prematurely into the resting (telogen) phase. Shedding typically becomes noticeable a few months after the triggering event.

Common triggers include:

  • Childbirth and pregnancy termination (the rapid drop in estrogen and progesterone pushes many follicles into rest at once)
  • Starting or stopping birth control pills
  • Medication changes
  • Major surgery, high fever, or severe illness
  • Acute psychological stress

Thyroid imbalance deserves special attention. Too much or too little thyroid hormone can shock the system into telogen effluvium, and as many as 70% of scalp hairs can fall out within about two months during such an episode.

Nutrition matters as well. Low ferritin (iron deficiency) has been directly linked to diffuse, nonscarring hair loss, and nutritional deficiencies are estimated to contribute to 10% to 20% of nonscarring alopecia cases.

The defining clinical feature: hair typically recovers once the underlying stressor is identified and addressed, making this the most reversible major category.

The Clinical Response: Finding and Fixing the Trigger

Treatment starts with root-cause identification: bloodwork for thyroid function and ferritin levels, a review of medications, and a history of recent life events. Correcting the underlying issue through iron supplementation, thyroid regulation, or medication adjustment typically resolves shedding over several months. Minoxidil may be used supportively to encourage faster regrowth.

One important caveat: increased shedding can also be an early sign of androgenetic alopecia. A telogen effluvium episode sometimes unmasks a second, permanent condition, a point covered in the overlap section below.

Category 3: Anagen Effluvium (Chemical and Radiation-Induced Loss)

Anagen effluvium is hair loss caused by chemicals or radiation, most commonly chemotherapy or radiation treatment for cancer. Unlike telogen effluvium, it disrupts hair during its active growth (anagen) phase, resulting in far more rapid and severe shedding, often within days to weeks of exposure. Certain toxic exposures, including some heavy metals and medications outside of chemotherapy, can also trigger it.

The Clinical Response: Timing and Supportive Care

Regrowth is generally expected once the causative treatment or exposure ends, because follicles are typically not permanently destroyed. Supportive measures include scalp cooling during chemotherapy to reduce severity, gentle hair care during regrowth, and cosmetic options such as wigs or scalp micropigmentation during the interim. New hair may temporarily differ in texture or color. This category requires coordination with the oncology or medical team rather than standalone hair restoration during active treatment.

Category 4: Alopecia Areata (Autoimmune Hair Loss)

Alopecia areata is an autoimmune condition in which the immune system attacks hair follicles, typically producing sudden, well-defined round or oval patches. Severity varies widely, from a single small patch to alopecia totalis (total scalp loss) and alopecia universalis (total body hair loss). The course is unpredictable: hair may regrow spontaneously, remain absent, or relapse and remit over years.

Other systemic and autoimmune diseases, such as lupus, can also cause hair loss ranging from thinning to clumps falling out, which underscores the value of a thorough medical evaluation.

The Clinical Response: A Rapidly Advancing Treatment Landscape

JAK inhibitors are now considered the first-line treatment for severe alopecia areata, including totalis and universalis. Three carry FDA approval:

  • Olumiant (baricitinib), approved in 2022
  • Litfulo (ritlecitinib), approved in 2023
  • Leqselvi (deuruxolitinib), approved in 2024

These represent a major shift from older, less targeted therapies. Corticosteroid injections and topical immunotherapy remain relevant for milder or localized cases. Because the condition is autoimmune, it requires dermatological management rather than surgical restoration, at least until disease activity is controlled.

Category 5: Traction Alopecia and Trichotillomania (Mechanical and Self-Induced Loss)

Traction alopecia results from hairstyles that continually pull at the hair, including tight ponytails, braids, weaves, and extensions. Repeated tension gradually damages follicles at the stress points, often along the hairline and temples.

Trichotillomania is a compulsive hair-pulling disorder. It differs from traction alopecia in that its root driver is behavioral and psychological rather than purely mechanical, so it often requires behavioral intervention alongside hair-focused care.

Reversibility depends on timing. Caught early, traction alopecia is reversible once tension is removed. Left unaddressed for years, it can progress to permanent, scarring follicle loss.

The Clinical Response: Behavioral Change and Timing-Dependent Treatment

The first step is eliminating the cause: changing styling practices or addressing compulsive pulling, ideally with therapeutic support. Early-stage traction alopecia often regrows fully once tension stops. Advanced cases with permanent follicle damage may benefit from surgical restoration, but only after the behavior or styling pattern has been resolved and hair loss has stabilized.

Category 6: Scarring (Cicatricial) Alopecia

Scarring alopecia is a group of conditions in which inflammation permanently destroys hair follicles and replaces them with scar tissue. By definition, the loss is irreversible. Although scarring types account for a small minority of cases compared with the roughly 95% that are nonscarring, they require the most urgent diagnosis, because delay allows destruction to spread.

Central centrifugal cicatricial alopecia (CCCA) is the most common type of hair loss seen in women with darker skin tones, according to the American Academy of Dermatology. This illustrates how scarring alopecia can disproportionately affect certain populations.

Tinea capitis, a fungal scalp infection, can mimic or contribute to scarring patterns. It causes patches of hair loss that may be red and scaly and must be treated with systemic (oral) medication. Hair typically regrows if the infection is resolved before permanent scarring sets in.

Unlike the other five categories, waiting is the highest-risk choice here.

The Clinical Response: Stop Progression, Then Restore

The first goal is halting active inflammation through dermatological management, using topical or oral anti-inflammatory or immunosuppressive therapy. Regrowth is not the aim, since destroyed follicles cannot be revived medically. Once inflammation has been confirmed inactive for a sustained period, hair transplantation into stabilized scarred areas may be considered. Treating scarring alopecia as if it were pattern hair loss would waste valuable time while damage continues.

When Causes Overlap: Complex and Mixed Presentations

Multiple categories can coexist in the same person, a nuance most resources overlook.

The best-documented overlap involves telogen effluvium and androgenetic alopecia. Increased shedding can be an early feature of pattern hair loss, and a true telogen effluvium episode can be the event that first makes previously subtle androgenetic alopecia noticeable. When the shedding resolves, the underlying pattern loss remains.

Patients of color may also present with more than one concurrent alopecia type, which makes trichoscopic and dermatological evaluation especially important. Self-diagnosis based on a single matching symptom can easily miss a second condition.

The 2026 Development to Know: GLP-1 Weight-Loss Drugs and Hair Loss

For anyone using or considering GLP-1 medications for weight loss or diabetes, a 2026 BMJ study of more than 12,000 users is worth knowing about. It found a 37% higher risk of hair thinning compared with SGLT-2 inhibitors and a 68% higher risk compared with DPP-4 inhibitors.

The reassuring part: the link was specific to nonscarring alopecia, meaning hair could potentially grow back. Functionally, this places it within the telogen effluvium category, likely driven by rapid weight loss and metabolic stress on follicles.

Context matters. Absolute risk remains low, roughly 3 to 9 cases per 1,000 person-years, with noticeable thinning most commonly appearing two to four months after starting treatment. Zepbound trial data revealed a notable gender gap, with hair loss reported in 7.1% of females versus 0.5% of males.

Anyone noticing shedding after starting a GLP-1 medication should consult both the prescribing physician and a hair specialist rather than assuming permanent loss or stopping the medication independently.

How to Identify Your Likely Category: A Diagnostic Path

A practical starting point is the shedding pattern:

  • Diffuse thinning or sudden shedding: Consider telogen effluvium, anagen effluvium, or early female pattern loss.
  • Well-defined patches: Consider alopecia areata, tinea capitis, or trichotillomania.
  • Receding or thinning in specific zones: Consider androgenetic alopecia.
  • Loss confined to styling tension areas: Consider traction alopecia.
  • Patches with redness, scaling, itching, or shiny skin: Seek evaluation promptly for scarring alopecia.

A specialist will typically ask about onset speed (sudden or gradual), family history, recent illness, medications, or childbirth, hairstyle habits, and any scalp inflammation or tenderness. Diagnosis is then confirmed with tools such as trichoscopy (magnified scalp examination), pull tests, bloodwork (ferritin and thyroid panel), and sometimes a scalp biopsy when scarring alopecia is suspected.

This self-assessment is a starting hypothesis, not a diagnosis. The standard of care is for board-certified dermatologists and hair restoration specialists to confirm the cause before recommending treatment.

From Diagnosis to Decision: What a Specialist Consultation Adds

Matching treatment to the actual underlying cause, rather than applying a generic solution, is the factor most likely to determine success. A comprehensive consultation includes a medical history review, scalp examination, discussion of progression, and a personalized recommendation spanning medical therapy, non-surgical options, or surgical restoration.

For progressive or permanent categories (androgenetic alopecia, advanced traction alopecia, stabilized scarring alopecia), surgical options such as FUE or FUT may be appropriate once medical management is optimized or inflammation is controlled. For reversible categories (telogen effluvium, anagen effluvium, early traction alopecia), the specialist’s role is often to confirm the diagnosis, rule out overlapping permanent causes, and monitor recovery rather than proceed to surgery.

That clinical rigor is what patients should expect from any specialist. At Hair Transplant Specialists, the team includes board-certified surgeons with more than 100 years of combined experience, led in part by Dr. Sharon Keene, a former President of the International Society of Hair Restoration Surgery (ISHRS).

Conclusion: Knowing Your Category Is the First Step Toward a Solution

Hair loss is not one condition but six distinct clinical categories, each with its own mechanism, reversibility profile, and treatment path. Some causes resolve once triggers are addressed, including telogen effluvium, anagen effluvium, and early traction alopecia. Others, such as androgenetic alopecia, alopecia areata, and scarring alopecia, are progressive, unpredictable, or permanent and require ongoing medical or surgical management.

Because overlap is common and self-diagnosis has real limits, professional evaluation prevents wasted time on the wrong approach. Understanding “why” is the necessary first step; a personalized clinical assessment turns that understanding into an effective plan.

Ready to Identify Your Cause and Your Path Forward?

Rather than continuing to guess based on symptoms, readers can schedule a consultation with Hair Transplant Specialists for a personalized diagnosis. The practice offers a full spectrum of care, from medical therapy (finasteride, minoxidil) and non-surgical treatments (PRP, low-level light therapy, Alma TED, exosomes) to advanced surgical restoration (FUE, FUT) and scalp micropigmentation.

The consultation is educational and low-pressure: a logical next step after learning about the causes, not a sales pitch.

Contact Hair Transplant Specialists

  • Phone: (651) 393-5399 or (651) 395-5366
  • Location: 2121 Cliff Dr. Suite 210, Eagan, MN 55122 (at Nicols Road and Cliff Drive, across from McDonald’s)
  • Hours: Monday to Thursday, 9:00 AM to 5:00 PM; Friday, 9:00 AM to 3:00 PM; Saturday and Sunday by appointment only
  • Website: INeedMoreHair.com